Class / Patent application number | Description | Number of patent applications / Date published |
424780260 | Chemical treating agent contains element other than C, H, O, alkali, or alkaline earth metal | 85 |
20100239521 | METHOD FOR THE PREPARATION OF MICRO- AND NANO-SIZED CARRIER SYSTEMS FOR THE ENCAPSULATION OF BIOACTIVE SUBSTANCES - The various embodiments herein provide a method for producing a carrier system for the encapsulation or entrapment of a bioactive agent. According to one embodiment herein, producing a carrier complex of a bioactive ingredient disposed within a carrier material, the method comprising the steps of: (a) providing a complexation zone supplied with an aqueous medium containing the carrier material; (b) simultaneously stirring and heating the aqueous medium; (c) adding the bioactive ingredient to the aqueous medium and maintaining the complexation zone under conditions of temperature effective to facilitate complexation of the bioactive ingredient by the carrier material; and (d) recovering from the complexation zone a carrier complex of the bioactive ingredient. | 09-23-2010 |
20110250164 | Antimicrobial Copolymer for Coating Surfaces, Obtained by Derivatization of a Vinylamine-Vinylalcohol Copolymer - A composition including the reaction product of at least a vinylamine-vinyl alcohol copolymer; an epoxyalkane; and a fluorocarbon that includes a reactive portion capable of reacting with the vinylamine-vinyl alcohol copolymer. Articles including coatings of such compositions, methods of preparing antimicrobial water-repellant surfaces and methods of preparing an antimicrobial water-repellant composition are also included. | 10-13-2011 |
20130108574 | RADIOPAQUE, NON-BIODEGRADABLE, WATER-INSOLUBLE IODINATED BENZYL ETHERS OF POLY(VINYL ALCOHOL), PREPARATION METHOD THEREOF, INJECTABLE EMBOLIZING COMPOSITIONS CONTAINING THEREOF AND USE THEREOF | 05-02-2013 |
20150335779 | Method of Embolization using a Radiopaque, Non-Biodegradable, Water-Insoluble Iodinated Benzyl Ether of PolyI(Vinyl Alcohol) - A method of embolizing an area of treatment includes providing a composition that includes a radiopaque, non-biodegradable, water-insoluble iodinated benzyl ether of poly(vinyl alcohol) consisting of a poly(vinyl alcohol) (PVA) having covalently grafted thereon iodinated benzyl groups comprising from 1 to 4 iodine atoms per benzyl group as the only substituents wherein a grafted repeating unit has formula (I) | 11-26-2015 |
20160024233 | SEQUESTRANTS OF ADVANCED GLYCATION END PRODUCT (AGE) PRECURSORS - Sequestrants of AGE precursors comprise amines separated by 2, 3 or 4 carbons. Sequestrants of AGE precursors can be used as pharmaceutical agents and in pharmaceutical compositions. The sequestrants of AGE precursors are particularly useful binding AGE precursors and dietary dicarbonyls in mammals in the gastrointestinal tract for the treatment of ailments such as diabetic nephropathy, chronic renal disease, atherosclerosis, stroke, cataracts, and Alzheimer's disease. | 01-28-2016 |
20160051577 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS - Disclosed herein are novel compositions and methods for treating or preventing upper GI tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H | 02-25-2016 |
424780270 | Nitrogen or sulfur | 79 |
20080226583 | THERAPEUTIC POLYESTERS AND POLYAMIDES - Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided. | 09-18-2008 |
20090098083 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS - The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments. | 04-16-2009 |
20090136443 | Drug Carrier - The present invention has an object of providing a drug carrier capable of controlling in vivo pharmacokinetics. The present invention is directed to a drug carrier comprising a molecular assembly having a drug incorporated therein, and the above object can be achieved by a part of the amphiphilic molecules included in the molecular assembly being released from the molecular assembly by an external environmental change. The present invention utilizes a phenomenon that the hydrophilic-hydrophobic balance of the amphiphilic molecules is shifted toward hydrophilicity by an external environmental change and thus the amphiphilic molecules are freed from the molecular assembly. | 05-28-2009 |
20100003212 | POLYMERS WITH ANTIMICROBIAL ACTIVITY CONTAINING QUATERNARY AMMONIUM GROUPS - The present invention relates to novel articles and the like, typically exhibiting antimicrobial efficacy which articles contain for example a carrier, a spacer attached to the carrier and one or more quaternary ammonium groups attached directly or indirectly to said spacer. | 01-07-2010 |
20110076246 | THIOL-CONTAINING COMPOUNDS FOR THE REMOVAL OF ELEMENTS FROM CONTAMINATED MILIEU AND METHODS OF USE - Sulfur-containing ligands and methods of their utilization for binding metals and/or main group elements and removing them from fluids, solids, gases and/or tissues are disclosed. The ligands are of the general structure: | 03-31-2011 |
20110110882 | CROSS-LINKED COMPOSITIONS - Improved compositions comprising a cross-linkable protein or polypeptide, and a non-toxic material which induces cross-linking of the cross-linkable protein. The compositions are optionally and preferably prepared in a non-phosphate buffer solvent. Optionally and preferably, the cross-linkable protein includes gelatin and any gelatin variant or variant protein as described herein. Optionally and preferably, the non-toxic material comprises transglutaminase (TG), which may optionally comprise any type of calcium dependent or independent transglutaminase, which may for example optionally be a microbial transglutaminase (mTG). | 05-12-2011 |
20110171167 | Isocyanate-Based Compositions and Their Use - The present disclosure describes a method and a kit for bulking, augmenting or occluding a tissue comprising administering a sufficient amount of a composition containing a biocompatible, non-bioabsorbable isocyanate-based material onto or into tissue. | 07-14-2011 |
20120003176 | HYDROGEL-FORMING COMPOSITION COMPRISING NATURAL AND SYNTHETIC SEGMENTS - A hydrogel composition is formed from a natural polymer derivative having a plurality of cross-linkable units depending therefrom, and a synthetic polymer derivative having a plurality of cross-linkable units depending therefrom, said natural and synthetic polymer derivatives having hydrolysable units disposed between the polymer backbone of said derivative and at least some of said cross-linkable units. The use of a combination of natural and synthetic polymers provides for biodegradability of the hydrogel, along with mechanical properties such as strength and elasticity. | 01-05-2012 |
20120058077 | BIOSTATIC POLYMER - Methods and compositions effective for at least a week for prevention of microbial colony growth on a surface, for example an inanimate surface, where the surface is covered with a dry or substantially dry film formed from a composition comprising a polyvinyl alcohol and a quaternary ammonium compound. The film may be formed in situ by coating the surface with a solution or emulsion comprising a polyvinyl alcohol and a quaternary ammonium compound and then causing or allowing it to dry or substantially dry. | 03-08-2012 |
20120093763 | RNA VIRUS INFECTION INHIBITOR, METHOD FOR INHIBITION OF INFECTION BY RNA VIRUS, RNA VIRUS INFECTION-INHIBITING PRODUCT, AND USE AS RNA VIRUS INFECTION INHIBITOR - Disclosed herein is an RNA virus infection inhibitor that is capable of effectively inhibiting humans from being infected with RNA viruses to prevent the occurrence of symptoms or, even when symptoms occur, to relieve the symptoms and is less likely to cause unexpected discoloration or discoloration under normal service conditions. The RNA virus infection inhibitor comprises an RNA virus infection-inhibiting compound comprising a linear polymer having, in its side chain, at least one of substituents having structural formulas represented by general formulas (1) to (3). | 04-19-2012 |
20120107264 | NUCLEIC ACID DELIVERY COMPOUNDS - Polymers including two or more different recurring units are disclosed herein. Also disclosed herein are methods of using such polymers to deliver nucleic acids to a cell. | 05-03-2012 |
20120141409 | MULTI-VALENT ADJUVANT DISPLAY - The present invention provides an adjuvant-polymer construct comprising a polymer backbone which is covalently linked to 3 or more adjuvants, wherein the 3 or more adjuvants are each present in a pendant side chain, the adjuvants being connected to the polymer backbone either directly or via a spacer group. | 06-07-2012 |
20120189571 | NANOSCALE PLATINUM COMPOUNDS AND METHODS OF USE THEREOF - The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention. | 07-26-2012 |
20120276041 | CONFORMABLE SOLVENT-BASED BANDAGE AND COATING MATERIAL - A biological coating material that includes a polymerizable polyacrylate monomer; a volatile liquid; a polymer selected from a synthetic rubber, a natural rubber, and a thermoplastic elastomer. The biological liquid coating material forms a coating or bandage in the form of a film that when applied and adhered to a surface or to the skin of a user inhibits the application surface from adhering to another surface. | 11-01-2012 |
20120328556 | Peptide Based Antimicrobial Coating - A comb-like surfactant polymer for changing the surface properties of biomaterials is described. The surfactant polymer comprises a polymeric backbone of repeating monomeric units having functional groups for chemically attaching to side chains, a plurality of hydrophobic side chains attached to the backbone via the functional groups and a plurality of hydrophilic side chains chemically attached via functional groups to the polymeric backbone. The hydrophilic side chains providing anti-thrombogenic properties to the surfactant. An antimicrobial agent selectively attached to some hydrophilic side chains thereby providing additional antimicrobial properties to the surfactant. The surfactant polymer may be applied to the surface of medical devices to reduce the surfaces thrombogenicity and decrease the number of microorganisms on the surface. | 12-27-2012 |
20130156722 | POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOF - Described herein are biodegradable drug delivery conjugates for effectively delivering bioactive agents to a subject. The drug delivery conjugates comprise a water-soluble high molecular weight linear biodegradable polymer backbone comprising a plurality of linear water-soluble polymeric segments connected to one another by a first (main-chain) cleavable linker, wherein a bioactive agent is covalently bonded to at least one water-soluble polymeric segment, at least one cleavable linker, or a combination thereof. The conjugates possess numerous advantages over prior art delivery conjugates. Also described herein are methods for making and using the conjugates. | 06-20-2013 |
20130156723 | SYNTHETIC STEREOISOMER PEPTIDES IN THE RETRO-INVERSO AND INVERSO CONFIGURATION, AND WITH CYCLIC AND LINEAR STRUCTURE, THEIR POLYMER CONJUGATES, THEIR ENCAPSULATION IN POLYMER PARTICLES, AND USES THEREOF - This invention discloses ligand-targeted multi-stereoisomer peptide-polymer conjugate compounds comprising a plurality of different synthetic and chemically modified stereoisomer peptides that have been conjugated to a biocompatible polymer carrying a peptide ligand for targeted delivery or encapsulated in ligand targeted polymer nanoparticles. The unique physicochemical properties of the stereoisomer peptides provide therapeutic compounds with ideal biopharmaceutical properties. The stereoisomer peptides carried by the polymer are delivered to cells or tissues to inhibit, suppress, block, or disrupt, simultaneously and independently, the functional domain of a different disease causing protein. Therefore the compounds are useful therapeutics for the treatment of abnormal angiogenesis and inflammation which are the hall mark of most human diseases including but not limited to cancer, metastasis, pathological conditions of the eye, cardiovascular, brain, and neurodegenerative disorders, diabetes, and diseases caused by infectious microorganisms. | 06-20-2013 |
20130171092 | ALPHA-CYANOACRYLATE ESTER SYNTHESIS - The high temperatures required for cracking the cyanoacrylate oligomers, produced by the Knovenagel condensation of formaldehyde and a cyanoacetate, limit the synthetic diversity and the number of different side chains that can be incorporated into a cyanoacrylate prepared using this method. Accordingly, the diversity of cyanoacrylate monomers prepared industrially is quite limited. Disclosed herein is a method for the preparation of alpha-Cyanoacrylate ester monomers from a variety of phosphonium and ammonium alpha-cyanoacrylate salts. The phosphonium and ammonium alpha-cyanoacrylate salts are of the general formula: | 07-04-2013 |
20130177523 | GOLD PARTICLES AND METHODS OF MAKING AND USING THE SAME IN CANCER TREATMENT - Described herein are gold particles that can be used to reduce tumor proliferation and treat cancer. In certain aspects, the gold particles can be modified in order to enhance selectivity and uptake of the particles by cancer cells. In certain aspects, the modified gold particles have a targeting group attached to the particle via a linker. The gold particles described herein can be used in combination with other anti-cancer agents in order to enhance overall cancer treatment. Methods for making and using the gold particles are also described herein. | 07-11-2013 |
20130195791 | CONJUGATES COMPRISING AN N-OXIME BOND AND ASSOCIATED METHODS - Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): | 08-01-2013 |
20130216494 | Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof - One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor. | 08-22-2013 |
20130236416 | SURFACE MODIFIED COLLOIDAL PARTICLES - The present invention generally relates to surface modified colloidal particles. The invention further relates to methods of preparing and methods of using the same. | 09-12-2013 |
20130243720 | Iron(II)-Containing A Treatments for Hyperphosphatemia - A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above. | 09-19-2013 |
20130287726 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF - A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed. | 10-31-2013 |
20130295040 | POLYMER - The application provides a method of producing a comb polymer comprising the steps of:
| 11-07-2013 |
20140030210 | DERIVATISATION OF BIOLOGICAL MOLECULES - The present disclosure relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula | 01-30-2014 |
20140056840 | HINDERED ALKYLAMINE POLYMER - The present invention relates to a polymer comprising hindered primary amine groups bonded to the backbone of the polymer by way of an amide, ester, or thioester linkage. The polymer is particularly useful as an adjuvant, especially for isothiazolone, and as a dispersant and stain blocker in coatings formulations. | 02-27-2014 |
20140056841 | Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms - Compositions are provided for promoting healing of tissue of a vertebrate organism. The compositions can be for internal administration of a therapeutically effective amount of pharmacologically active, protease inhibiting, aqueous media soluble polysulfonated materials in salt form and associated with a secondary material to reduce one or more of inflammation, bacterial proliferation, proteolytic activity, and cancerous cell growth. The compositions may additionally or alternatively be cross-linked so as to alter the solubility of these pharmacologically active salts or slow dissolution by providing biodegradable cross-linkers. Compositions for healing the tissue of a multicellular organism are provided that can include a polysulfonated material in a liquid mixture, as solid particles or constructs that may or may not biodegrade or deliver a pharmacologically relevant value. Some of the compositions are also provided for inclusion into a device for preventing infection, reducing inflammation, and preserving the activity of a protein or protein drug. | 02-27-2014 |
20140120054 | CATIONIC MICELLES WITH ANIONIC POLYMERIC COUNTERIONS COMPOSITIONS THEREOF - The invention relates to polymer-micelle complex. The polymer-micelle complexes include a positively charged micelle selected from the group consisting of a monomeric quaternary ammonium compound, a monomeric biguanide compound, and mixtures thereof. The positively charged micelle is electrostatically bound to a water-soluble polymer bearing a negative charge. The polymer does not comprise block copolymer, latex particles, polymer nanoparticles, cross-linked polymers, silicone copolymer, fluorosurfactant, or amphoteric copolymer. The compositions do not form a coacervate, and do not form a film when applied to a surface. | 05-01-2014 |
20140120055 | ANIONIC MICELLES WITH CATIONIC POLYMERIC COUNTERIONS COMPOSITIONS THEREOF - The invention relates to a polymer-micelle complex. The polymer-micelle complexes include a negatively charged micelle that is electrostatically bound to a water-soluble polymer bearing a positive charge. The polymer does not comprise block copolymer, latex particles, polymer nanoparticles, cross-linked polymers, silicone copolymer, fluorosurfactant, or amphoteric copolymer. The compositions do not form a coacervate, and do not form a film when applied to a surface. | 05-01-2014 |
20140120056 | ANIONIC MICELLES WITH CATIONIC POLYMERIC COUNTERIONS METHODS THEREOF - The invention relates to a polymer-micelle complex, The polymer-micelle complexes include a negatively charged micelle that is electrostatically bound to a water-soluble polymer bearing a positive charge. The polymer does not comprise block copolymer, latex particles, polymer nanoparticles, cross-linked polymers, silicone copolymer, fluorosurfactant, or amphoteric copolymer. The compositions do not form a coacervate, and do not form a film when applied to a surface. | 05-01-2014 |
20140127153 | AQUEOUS OLIGOMER / POLYMER EMULSION WITH CATIONIC FUNCTIONALITY - An aqueous emulsion comprising at least a covalently bound vinyl oligomer and vinyl polymer, wherein said vinyl oligomer comprises 5 to 85 mol % of vinyl monomers bearing quaternary ammonium ion functional groups or quaternisable amine functional groups and is obtained by a controlled radical polymerisation of at least one vinyl monomer via a reversible addition-fragmentation chain transfer mechanism in solution in the presence of a control agent and a source of free radicals; wherein said vinyl polymer is obtained by emulsion polymerisation of vinyl monomers in the presence of the vinyl oligomer; wherein the weight % ratio of vinyl oligomer to vinyl polymer is in the range of from 0.5:99.5 to 65:35. | 05-08-2014 |
20140212372 | HYDROGELS COMPRISING CROSSLINKED POLYMERS CONTAINING BIOMASS DERIVED MATERIALS - Novel, crosslinked polymers using biomass derived materials, such as aldaric acids and derivatives, are provided. The polymers can be used as hydrogels and in antimicrobial compositions. | 07-31-2014 |
20140294751 | Hemocompatibility Modifiers for Cross-Linked Polymeric Material - The invention concerns methods of treating blood, blood product, or physiologic fluid to provide at least one of (i) increasing shelf life of the blood, blood product or physiologic fluid, (ii) maintaining freshness of new blood, blood product or physiologic fluid, and (iii) removing undesirable molecules from the blood, blood product or physiologic fluid; said method comprising contacting said blood, blood product or physiologic fluid with a sorbent, said sorbent being primarily in a plurality of solid forms and comprising a cross-linked polymeric material having a plurality of at least one of (1) zwitterionic moieties and (2) oligo(ethylene glycol) moieties attached to the surface of said cross-linked polymeric material. | 10-02-2014 |
20140308235 | METAP2 Inhibitors and Methods of Treating Obesity - The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors. | 10-16-2014 |
20150056157 | VASCULAR DELIVERY SYSTEMS - The site-specific expression of selectins on endothelial cells of blood vessels during angiogenesis provides an opportunity to target anti-cancer drugs to the vascular endothelium to extend the range of the therapeutic effect. This invention describes an innovative drug targeting strategy for the selective delivery of the anticancer drugs to endothelial cells by means of polymer-drug conjugates modified with a carbohydrate ligand for the vascular selectins. A model chemotherapeutic drug, doxorubicin, and the E-selectin ligand, sLex, are attached to a biocompatible polymer (HPMA). The selective binding, cellular uptake, intracellular fate, and cell cytotoxicity of the polymer-bound drug are investigated in human endothelial cells. | 02-26-2015 |
20150079020 | INJECTABLE HYDROGELS - The present disclosure generally relates to injectable compositions. More particularly, the present disclosure relates to injectable, thermogelling hydrogels and associated methods. In one embodiment, the present disclosure provides for a composition comprising a poly(N-isopropylacrylamide)-based macromer and a polyamidoamine-based macromer. | 03-19-2015 |
20150104408 | Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery - The present invention is directed membrane active poly(acrylate) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides cells in vivo. RNAi polynucleotides are conjugated to the poly(acrylate) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(acrylate) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness. | 04-16-2015 |
20150118178 | CONJUGATES COMPRISING AN N-OXIME BOND AND ASSOCIATED METHODS - Conjugates comprising a N-oxime bond are disclosed. In one embodiment, a suitable conjugate is represented by the following Formula (I): | 04-30-2015 |
20160009872 | THIOLATED PEG-PVA HYDROGELS | 01-14-2016 |
20160051692 | NOVEL METHODS OF USE OF BIOMIMETIC PROTEOGLYCANS - In one aspect, the present invention relates to a new method of treating or preventing urinary incontinence in a mammal in need thereof. In certain embodiments, the method comprises contacting a composition comprising at least one biomimetic proteoglycan with the urethral or periurethral tissue of the mammal. | 02-25-2016 |
20160184344 | STIMULI RESPONSIVE COMPOSITIONS FOR IRON CHELATION - The present technology provides new compositions comprising at least one cross-linked co-polymer. In some embodiments, the polyacrylamide co-polymer comprises water soluble subunits, cross-linking subunits, and iron chelating subunits. In other embodiments, the co-polymer comprises water soluble units, cross-linking subunits, and substituted subunits, which can be conjugated with iron-chelating agents. When these new particles are exposed to certain environments, such the presence of strong acids or oxidation agents, these particles are capable of breaking up so that the iron chelating agents can chelate iron or other metals from their environments. Methods to prepare these new compositions are also provided. These compositions or compositions comprising nanogels of the present technology may be used to treat metal overload conditions such as iron overload resulting from chronic transfusions. | 06-30-2016 |
20160184345 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF - One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor. | 06-30-2016 |
20160199266 | TWO- AND THREE-COMPONENT SILOXANE AND RELATED COMPOUNDS AND COMPOSITIONS | 07-14-2016 |
20160199501 | FACTOR VIII ZWITTERIONIC POLYMER CONJUGATES | 07-14-2016 |
20170231227 | ANTIFUNGAL-GRAFTED POLYOLEFIN | 08-17-2017 |
20180021370 | PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATION | 01-25-2018 |
424780280 | Sulfur heterocycle | 2 |
20110305660 | OMEGA-FUNCTIONALIZED POLYMERS, JUNCTION-FUNCTIONALIZED BLOCK COPOLYMERS, POLYMER BIOCONJUGATES, AND RADICAL CHAIN EXTENSION POLYMERIZATION - Polymeric compounds having spatially controlled bioconjugation sites are described. Functionalization is achieved by selective co-terminal chain extension of polymer chains by radical polymerization, such as reversible addition-fragmentation chain transfer (RAFT) polymerization. | 12-15-2011 |
20160038528 | Rapidly Adaptable Nano Therapeutics for Treatment of Infectious Disease - The invention relates to rapidly adaptable nanotherapeutics. The therapeutics are nucleic acid molecules, such as, RNA, DNA, or modified-DNA. The nucleic acid therapeutics are preferably administered as a nanoparticle composition, further containing one or more synthetic polymers. The therapeutics are rapidly adaptable because the identification and design of the polynucleotide sequence containing the therapeutic sequence is based upon rapid computer-implemented bioinformatics and nucleic acid synthesis protocols. The rapid adaptable protocols differ from traditional methods of antibiotic and antipathogenic drug development, which are slow and do not address drug resistance issues. Furthermore, the invention encompasses a facility with dedicated apparatus for practicing the invention in military theater or where emerging pathogenic threats are located. This facility may be mobile and transportable as a dedicated unit. | 02-11-2016 |
424780290 | Nitrogen heterocycle | 30 |
20110044931 | MULTI-CONJUGATE OF SIRNA AND PREPARING METHOD THEREOF - The present invention relates to a multi-conjugate of small interfering RNA (siRNA) and a preparing method of the same, more precisely a multi-conjugate of siRNA prepared by direct binding of double stranded sense/antisense siRNA monomers or indirect covalent bonding mediated by a cross-linking agent or a polymer, and a preparing method of the same. The preparing method of a siRNA multi-conjugate of the present invention is characterized by simple and efficient reaction and thereby the prepared siRNA multi-conjugate of the present invention has high molecular weight multiple times the conventional siRNA, so that it has high negative charge density, suggesting that it has excellent ionic interaction with a cationic gene carrier and high gene delivery efficiency. | 02-24-2011 |
20120014908 | TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF - The present disclosure provides inter alia conjugates of formula (I): wherein n, R1, R2, Rx, Z, X, Y and Z are as defined herein. A conjugate of formula (I) can also be converted to a conjugate of formulae (II) or (III) as described herein. Without limitation, the conjugates can be used to make controlled release materials and chemical sensors. | 01-19-2012 |
20120148521 | Methods and Compositions for Controlled Release of Drugs - Methods and compositions for controlled release of amine, alcohol and thiol drugs, e.g., narcotic analgesics, and tricyclic amine antidepressants, are provided. The drug is releasably covalently bonded to a polymer or other activity-blocking moiety. Release is by an unmasking reaction resulting in the formation of a chemical group that undergoes a second reaction releasing the drug. For example, the narcotic analgesic fentanyl covalently attached to an inert polymer by way of its nitrogen through formation of a quaternary vinylammonium salt is released by hydrolysis of an acetal exposing an alcohol that undergoes an intramolecular nucleophilic substitution reaction involving displacement of the fentanyl nitrogen. Process rate is controlled by controlling the rate of the intramolecular substitution reaction through varying the number of atoms in the chain connecting the alcohol group and the vinylic carbon and/or by the addition of substituents on that chain, and/or by the acetal hydrolysis rate. | 06-14-2012 |
20120230938 | Polyconjugates for In Vivo Delivery of Polynucleotides - The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible or labile linkages connecting component parts provides for physiologically responsive activity modulation. | 09-13-2012 |
20120251482 | USE FOR IMPROVING 5-HT FUNCTION AND ENOS EXPRESSION OF KMUPS AMINE SALTS - The synthesized piperazium salt of KMUPs disclosed in the present invention is characterized by presented pharmaceutics having functions to improve 5-HT function and eNOS expression of KMUPS in lung diseases, such as proliferation, obliteration, pulmonary artery hypertension. The pharmaceutical composition for inhibiting monocrotaline (MCT)-induced proliferation of pulmonary artery includes an effective amount of a complex salt of formula (I): | 10-04-2012 |
20120282211 | ANTIBODIES AND CONJUGATES FOR MODULATORS OF ANGIOGENESIS - We provide methods and compositions for the treatment of dysregulation of blood vessel growth by regulation of neovascularization. Embodiments accomplish this by restricting the diffusion and transport of therapeutic agents through conjugating them to polymers or polymer constructs while retaining the binding affinities and functions of the therapeutic agents. | 11-08-2012 |
20120321584 | PROCESSES FOR PREPARING AMINE SALTS OF KMUP-3 AND USE THEREOF - An inhibiting heart failure disease pharmaceutical composition is provided.
| 12-20-2012 |
20130011363 | CATIONIC BETAINE PRECURSORS TO ZWITTERIONIC BETAINES HAVING CONTROLLED BIOLOGICAL PROPERTIES - Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, therapeutic agent delivery systems that include the cationic polymers, methods for administering a therapeutic agent using the delivery systems, and methods for making and using the cationic polymers, monomers, surfaces, and therapeutic agent delivery systems. | 01-10-2013 |
20130028857 | SYNTHETIC NANOCARRIERS COMPRISING POLYMERS COMPRISING MULTIPLE IMMUNOMODULATORY AGENTS - This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise polymers that comprise at least two immunomodulatory agent moieties. | 01-31-2013 |
20130034517 | TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES - The present invention provides random copolymers containing phosphorylcholine and one or more functional agents, and methods of preparing such random copolymers. | 02-07-2013 |
20130095059 | INHALED NO DONOR KMUPS DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION VIA SUPPRESSED CYTOKINES, INOS AND INFLAMMATORY CELL COUNTS IN ASTHMA MODEL - A method for treating a disease is provided. The method includes steps of: providing a subject in need thereof; and administering one selected from a group consisting of KMUPS compound represented by formula I, a pharmaceutically acceptable salts thereof; and a pharmaceutical composition thereof to the subject in a dosage from 1 to 2.5 milligram per kilogram of body weight, | 04-18-2013 |
20130202549 | USE OF DPAS AND CO-POLYMERS FOR HYPERLIPIDEMIA AND ATHEROSCLEROSIS ALONG WITH REDUCING FEEDING RATE AND ADIPOSE TISSUE WEIGHT OF OBESITY ANIMAL - The disubstituted piperazine analogs (DPAs) derivative compound and DPAs amine complex compound disclosed in the present aspects have characterized by presented pharmaceutics having functions to improve lipolysis, such as inhibiting obesity hyperlipidemia, and atherosclerosis. | 08-08-2013 |
20130302268 | ACTIVE PRINCIPLE FOR MITIGATING UNDESIRED MEDICAL CONDITIONS - A composition for treating or preventing inflammatory-related conditions includes as an active principle a carrier which exhibits a plurality of a scavenger structure capable of mitigating the activity of a mediator of inflammatory-related conditions. The scavenger structure includes a nucleophilic centre complying with the formula X | 11-14-2013 |
20140037573 | CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS - Particles and conjugates for delivering nucleic acid agents. Compositions containing the particles, the conjugates, or both. Methods of using the particles, the conjugates, and the compositions. | 02-06-2014 |
20140112881 | CROSSLINKED POLYMER NANO-ASSEMBLIES AND USES THEREOF - The invention provides a novel system of nano-assemblies and related method for delivery of therapeutic, diagnostic or imaging agent to biological sites. The compositions and methods of the invention enable the syntheses of novel polymeric nano-assemblies (nanoparticles) under non-emulsion conditions with the incorporation of hydrophobic guest molecules. The versatilities and advantages of the polymer nanoparticles of the invention include: (i) the guest molecules (e.g., drug molecules) can be readily incorporated non-covalently within the nanoparticles; (ii) the surface of the nanoparticles are functionalizable; (iii) the non-covalently encapsulated guest molecule (payload) can be released in response to a biologically relevant stimulus at the target site; (iv) the payload is held by the polymeric nanoparticle before being internalized in cells and can be released within the cellular interiors; (v) encapsulating lipophilic small molecules within its crosslinked interiors and binding proteins on its surface through electrostatic interactions; (vi) facile synthetic methods for ligand functionalization that can be utilized to decorate nanogels with cell targeting ligands that facilitate receptor-dependent cellular uptake, and (vii) the payload release kinetics is tunable and controllable. | 04-24-2014 |
20140219950 | ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS - Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontophoresis, and/or electrophoresis can also be used with the disrupting agents. | 08-07-2014 |
20140294752 | METHOD FOR NUCLEIC ACID DELIVERY USING HYALURONIC ACID - A hyaluronic acid conjugates including hyaluronic acid, a disulfide bond-containing crosslinking agent, and a cationic, amphiphilic polymer; a hyaluronic acid-nucleic acid complex in which a nucleic acid is bound to the hyaluronic acid conjugate; a composition in which the hyaluronic acid-nucleic acid complexes are crosslinked with each other; a nucleic acid delivery composition including the hyaluronic acid-nucleic acid complex; and a method of nucleic acid delivery using the hyaluronic acid-nucleic acid complex. | 10-02-2014 |
20140314704 | Treatment of B Cell Lymphomas - Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided. | 10-23-2014 |
20140356315 | TRIBLOCK COPOLYMER AND USE THEREFOR - Provided is a triblock copolymer represented by General Formula (I): | 12-04-2014 |
20150056158 | BRANCHED POLYMERS - The present invention relates to branched polymer comprising a support moiety and at least three block co-polymer chains covalently coupled to and extending from the moiety, wherein: (i) each of the at least three block co-polymer chains comprise (a) a cationic polymer block that is covalently coupled to a hydrophilic polymer block, or (b) a cationic polymer block that is covalently coupled to a hydrophobic polymer block, said hydrophobic polymer block being covalently coupled to a hydrophilic polymer block; and (ii) at least one of said covalent couplings associated with each of said block co-polymer chains is biodegradable. | 02-26-2015 |
20150071872 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS - The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker. | 03-12-2015 |
20150110732 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery - The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness. | 04-23-2015 |
20150118179 | BIOCIDAL COMPOUNDS AND METHODS FOR USING SAME - Biocidally active cationic analogs of N-halamine having two biocidally active groups covalently bonded together in a single molecule and having general Formula (I). Compounds of Formula (I), and precursors thereof, can be in solution form immobilized onto a substrate via physical coating or covalent chemical bonding to functionalize surfaces or added into materials as additives so as to render them biocidal. The biocidal solutions and substrates comprising the compounds or precursors of the present invention can then be used to inactivate pathogenic microorganisms. N-halamine-L-QUAT (I) wherein: the N-halamine may be a cyclic or acyclic N-halamine; L is C | 04-30-2015 |
20150132249 | STIMULI RESPONSIVE POLYESTER AMIDE PARTICLES - A composition including a solution suitable for introduction into a blood vessel comprising particles including a treatment agent and a tunable stimuli-responsive polymer. A method including introducing a delivery device into a blood vessel; and introducing a solution into the blood vessel, the solution including particles comprising a treatment agent and a tunable stimuli-responsive polymer. A method including combining a treatment agent and a tunable stimuli-responsive polymer; and forming particles of the combination suitable for delivery through a blood vessel. | 05-14-2015 |
20150306107 | SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia - The Substituted Amine Analogs (SAA) derivative compounds and SAA complex compounds disclosed in the present invention are characterized as compositions having the functions of inhibiting disorders caused by oxidative stress, and more particularly to those SAA derivative compounds capable of inhibiting disorders caused by oxidative stress because of neurodegenerative diseases, lung diseases, oxidative stress-induced heart disease and carvenosus dysfunction. | 10-29-2015 |
20150359798 | PIPERAZINYL DERIVATIVE REDUCES HIGH-FAT DIET-INDUCED ACCUMULATION OF FAT IN THE LIVERS, THERAPEUTICALLY - A method for inhibiting a liver disease is provided. The method includes administering a pharmaceutical composition of one of a piperazine analogue and a piperazine analogue complex to a warm-blooded animal suffering from the liver disease. | 12-17-2015 |
20150359901 | PIPERAZINYL DERIVATIVE REDUCES HIGH-FAT DIET-INDUCED ACCUMULATION OF FAT IN THE LIVERS, THERAPEUTICALLY - A method for inhibiting a liver disease is provided. The method includes administering a pharmaceutical composition of one of a piperazine analogue and a piperazine analogue complex to a warm-blooded animal suffering from the liver disease. | 12-17-2015 |
20150374663 | Compositions and Methods for Controlled Localized Delivery of Bone Forming Therapeutic Agents - The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3β. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation. | 12-31-2015 |
20160114958 | Chemotaxis Antibacterial Film and Package - An anti-bacterial package component comprising a packaging substrate having an anti-bacterial agent fixed thereto; and a chemoattractant (bacteria attractant) incorporated with the substrate and adapted for diffusion into a food or toiletry product medium; the attractant selected from the group consisting of monosaccharides, disaccharides, polysaccharides, vitamins, minerals and essential amino acids; wherein the attractant is adapted for biological transport of pathogenic or spoilage bacteria from a product medium in contact with the substrate across an attractant concentration gradient to contact with the fixed anti-bacterial agent whereby the bacteria is killed, immobilized, made steril, or otherwise rendered harmless. | 04-28-2016 |
20160175451 | ACTIVE PRINCIPLE FOR MITIGATING UNDESIRED MEDICAL CONDITIONS | 06-23-2016 |